113 related articles for article (PubMed ID: 10746678)
1. Preoperative chemoradiotherapy alters the expression and prognostic significance of adhesion molecules in Barrett's-associated adenocarcinoma.
Turner JR; Torres CM; Wang HH; Shahsafaei A; Richards WG; Sugarbaker D; Odze RD
Hum Pathol; 2000 Mar; 31(3):347-53. PubMed ID: 10746678
[TBL] [Abstract][Full Text] [Related]
2. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma.
Hornick JL; Farraye FA; Odze RD
Am J Surg Pathol; 2006 Jan; 30(1):28-35. PubMed ID: 16330939
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma.
Torres C; Wang H; Turner J; Shahsafaei A; Odze RD
Hum Pathol; 1999 Jul; 30(7):753-8. PubMed ID: 10414493
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 in premalignant and malignant Barrett's oesophagus.
Lagorce-Pages C; Paraf F; Dubois S; Belghiti J; Fléjou JF
Histopathology; 1998 Jan; 32(1):7-14. PubMed ID: 9522210
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
7. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
8. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.
Chung Y; Law S; Kwong DL; Luk JM
Dis Esophagus; 2011 Jan; 24(1):49-55. PubMed ID: 20807231
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis.
Böttger TC; Youssef V; Dutkowski P; Maschek H; Brenner W; Junginger T
Cancer; 1998 Sep; 83(6):1074-80. PubMed ID: 9740070
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.
Swami S; Kumble S; Triadafilopoulos G
Am J Gastroenterol; 1995 Oct; 90(10):1808-13. PubMed ID: 7572899
[TBL] [Abstract][Full Text] [Related]
13. GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma.
Pavlov K; Honing J; Meijer C; Boersma-van Ek W; Peters FT; van den Berg A; Karrenbeld A; Plukker JT; Kruyt FA; Kleibeuker JH
Dig Liver Dis; 2015 Jan; 47(1):73-80. PubMed ID: 25445407
[TBL] [Abstract][Full Text] [Related]
14. Pathologic prognostic factors in esophageal squamous cell carcinoma: a follow-up study of 74 patients with or without preoperative chemoradiation therapy.
Torres CM; Wang HH; Turner JR; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
Mod Pathol; 1999 Oct; 12(10):961-8. PubMed ID: 10530561
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.
Abdel-Latif MM; O'Riordan J; Windle HJ; Carton E; Ravi N; Kelleher D; Reynolds JV
Ann Surg; 2004 Apr; 239(4):491-500. PubMed ID: 15024310
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
[TBL] [Abstract][Full Text] [Related]
17. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of adenocarcinoma arising in Barrett's esophagus.
Hoff SJ; Sawyers JL; Blanke CD; Choy H; Stewart JR
Ann Thorac Surg; 1998 Jan; 65(1):176-80; discussion 180-1. PubMed ID: 9456113
[TBL] [Abstract][Full Text] [Related]
19. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques.
May A; Gossner L; Pech O; Müller H; Vieth M; Stolte M; Ell C
Endoscopy; 2002 Aug; 34(8):604-10. PubMed ID: 12173079
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction.
Koppert LB; Wijnhoven BP; Tilanus HW; Stijnen T; Van Dekken H; Dinjens WN
Int J Surg Pathol; 2004 Apr; 12(2):117-25. PubMed ID: 15173916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
